Emerging adults with type 1 diabetes (T1D) often find it challenging to manage their diabetes well due to the many competing priorities they are juggling during this time. The majority of emerging adults (72%) are already looking for health information online, so telemedicine may be an avenue to explore with them. Telemedicine services for individuals with T1D are becoming increasingly popular and have been found to be beneficial for those who use them. However, there are very few multi-component telemedicine services available for individuals with T1D, and none of them provide a comprehensive technology-based system. Additionally, while these multi-component T1D telemedicine systems often included emerging adults in the group under study, the average age of the study subjects was usually above the age range of emerging adulthood. This suggests that specific developmental needs of emerging adults are not being addressed by these telemedicine systems, nor are the issues faced by diverse populations. More research needs to be done to address which telemedicine services, if any, would be beneficial for this especially vulnerable population.

Mobile device and mobile internet use
The majority of emerging adults (72%) are already looking for health information online. Rates of mobile internet use and the use of mobile devices are highest in this age group and have been rising over the past decade. A Pew research study (2010) on mobile internet use in American teenagers and young adults identified that in the age group 18–29 years old, 93% go online, 93% own a cell phone, 66% own a laptop or netbook, and 81% are wireless internet users. Internet-based healthcare delivery is a novel way to target unmet needs in this population. This technologically-savvy group has the potential to greatly benefit from a multi-component, technology-based diabetes self-management (DSM) intervention that closes the gaps in their outcomes and limitations of multi-component telemedicine services that have been used with emerging adults with T1D over the past 10 years.

Benefits of telemedicine
Telemedicine services which utilize the internet, videoconferencing services, and apps to enhance diabetes care and self-management for individuals with T1D, are becoming increasingly popular. Glycemic and psychologic outcomes from telemedicine visits are equivalent to, or better than, in-person visits for both children and adults with T1D. Additional benefits of telemedicine are increased attendance at visits, less time spent traveling to and attending visits, and lower cost. In addition, the use of telemedicine versus in-person visits does not affect the therapeutic relationship between providers and adolescent patients, and may actually empower patients to better manage their diabetes.
A review of existing telemedicine systems for emerging adults with type 1 diabetes

While several telemedicine systems exist, very few multi-component T1D telemedicine systems targeting emerging adults have been described in the literature, and those that are reported are not fully comprehensive technology-based systems. Additionally, demographic data on race or ethnicity were not presented in any of the papers reviewed. Unless specified below, these studies took place in diabetes centers with largely white populations in the United States and Europe. A summary of these studies also appears in Table 1.

EncoDiab, a virtual community that includes DSM tools (carbohydrate counter, insulin dose calculator, and body mass index calculator), a library, and a chat room for chatting with peers and providers, was designed based on user feedback. However, it targeted 18–50-year-olds and not specifically emerging adults. The average age of the user was 34 years old, suggesting that even though EncoDiab represents a system designed by patients, it may not suffice specifically for emerging adults with T1D because it may not address emerging-adult-specific issues. Additionally, it does not contain a videoconferencing component.

In the TeleDiab 1 study, Diabeo—a smartphone app with an electronic logbook, a bolus calculator, automatic algorithms that can be used to make insulin dose or carbohydrate intake adjustments, and automatic data transmission to the diabetes clinicians’ computers—helped to improve glycemic control in a sample of 180 adults with T1D. After 6 months of use, glycated hemoglobin (HbA1c) had improved from 9.07 ± 1.07% at baseline to 8.63 ± 1.07% in subjects who only used the app (p=0.022) and 8.41 ± 1.07% in subjects who used the app and also received supplemental phone calls from their diabetes clinician every 2 weeks (p=0.0019). No change in HbA1c was seen in the control group (9.10 ± 1.16%, p=NS). The app did not contain an education piece; any education the subjects received during this study was given by the diabetes clinicians during the phone calls. There was also no videoconferencing as part of the study.

Similar to the EncoDiab study, the average age of subjects in the Diabeo study was 34 years old, suggesting that the outcomes of this study may not be representative of what may be found with emerging adults.

A post-hoc analysis of the Diabeo study analyzed subjects by high and low app use. Low users had 36% system use initially, and use decreased over the 6 months of the study. More emerging adults fell into the “lower user” category: low users’ median age was 25 years old versus a median age of 33 years old for high users (p=0.086). Information about subjects’ race/ethnicity, academic status, living situation, and profession were not given by app use group. The metabolic improvements that were seen in low users (HbA1c improved from 9.0% to 8.5%, p-value not given) were attributed to the app facilitating communication with diabetes clinicians.

The Medical Guard Diabetes (MGD) telemedicine system that was used in the Telemed study allowed automatic downloading of blood glucose meters directly into a secure website. It also allowed users to annotate the blood glucose readings and enter insulin dose and carbohydrate intake information. MGD was used in conjunction with monthly “telematic” visits and required feedback from diabetes clinicians within 3 days of a subject uploading diabetes data into the system. The “telematic” visits were not defined, and based on other telemedicine literature, could range from phone calls to videoconferencing. All subjects in the study had improvements in HbA1c after 6 months of study participation (HbA1c=9.2% at baseline and 8.6–8.7% at end of study, p=NS between groups but p<0.001 endpoint versus baseline), increased knowledge about their diabetes, and increased adherence to DSM tasks. Additionally, subjects in the intervention group spent significantly less time attending visits (353 ± 222 minutes versus 823 ± 645 minutes, p<0.0001), travel time included) and required significantly less time from the diabetes team (232 ± 89 minutes versus 288 ± 105 minutes, p<0.001). Furthermore, a lack of face-to-face encounters appeared to empower subjects to better manage their diabetes. As in the EncoDiab and Diabeo studies, the average age of study subjects was approximately 32 years old, suggesting that despite its benefits, this system may not specifically address the needs of emerging adults with T1D.

Two other pilot studies evaluated satisfaction and usability of different telemedicine systems. The first, a virtual clinic designed for insulin pump users, offered subjects access to their health information, communication with healthcare providers via email and “ask the expert” sessions, and interaction with peers. The system did not have videoconferencing, nor was it clear if there was an electronic logbook for blood glucose, insulin, and carbohydrate data. Users found participation in the virtual clinic reassuring; however, only 50% of subjects used the system at least weekly. The peer interaction piece was seen as the most valuable component (by 53% of subjects), followed by communication with healthcare providers (by 41%), and access to health information (by 24%). Subjects ranged in age from 22–70 years old, but were likely not emerging adults, as the average duration of diabetes was 24 years.

The second described a telemedicine system with both patient and provider platforms that was designed in Iran for use in developing countries where there is limited access to diabetes providers. The patient platform contained a logbook, data management capabilities, educational reading materials, that had been developed based on need and that had some embedded animations, and ways to contact the endocrinologist and the web administrator. The provider platform contained a list of patients who had updated records or messaged the endocrinologist, patient diabetes and demographic/medical data including data analysis capabilities, prescribing and medical advice (this was not further clarified), and a place to change their password. The system sent the providers email notifications if a patient had entered new data or if new messages had been sent to them. Most study participants were satisfied with the system. Of note, the system did not include any videoconferencing services and it had limited data entry based on the needs of the patient population being studied. Furthermore, it was presented to parents of pediatric patients with T1D and emerging adults with T1D, but the two groups’ results were not separated, presumably because of the small sample size.

The majority of telemedicine services described in the empirical literature are aimed towards either children, adolescents, or adults. Only one telemedicine consultation service specifically targeting emerging adults (18–25 years old) with T1D, entitled Colorado Young Adults with Type 1 Diabetes (CoYoT1) Clinic, has been reported in the literature, to date. It is also the only multi-component telemedicine system in the literature that is based in the United States. This year-long study employed videoconferencing services instead of in-person visits for three of the four American Diabetes Association-recommended quarterly follow-up visits and enabled peer support through video-based group visits. Study participants uploaded...
<table>
<thead>
<tr>
<th>Author</th>
<th>Study name</th>
<th>Description</th>
<th>Average age ± SD (Range)</th>
<th>N, % male</th>
<th>Outcomes</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raymond et al.</td>
<td>CoYoT1</td>
<td>Videoconferencing services with diabetes providers instead of in-person visits; peer support through video-based group visits; study participants uploaded insulin pumps, BG meters, and CGMs immediately prior to their visit</td>
<td>Control group 20.5 ± 1.9; Intervention group 19.8 ± 1.7, (18-25)</td>
<td>N=81</td>
<td>Intervention group: significantly increased attendance at visits; greater satisfaction with the care they received</td>
<td>Not a randomized controlled trial—study participants self-selected which group they were in</td>
</tr>
<tr>
<td>Reid et al.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alvarado-Martel</td>
<td>EncoDiab</td>
<td>Virtual community that includes DSM tools, a library, and a chat room</td>
<td>34 (18–50)</td>
<td>N=33, 54.5% M</td>
<td></td>
<td>System development No videoconferencing component; may not address issues specific to emerging adults</td>
</tr>
<tr>
<td>Charpentier et</td>
<td>TeleDiab 1</td>
<td>Diabeo app use (electronic logbook, bolus calculator, automatic algorithms for insulin dose or carbohydrate adjustments, and automatic data transmission to the diabetes clinicians’ computers) ± supplemental phone calls</td>
<td>33.8 ± 12.9</td>
<td>N=180, 36.7% M</td>
<td>Statistically significant improvement in HbA1c in those who used the app; further improvement in HbA1c with supplemental phone calls</td>
<td>No videoconferencing component; no education component in the app; may not address issues specific to emerging adults</td>
</tr>
<tr>
<td>Esmatjes et</td>
<td>Telemed</td>
<td>Used the Medical Guard Diabetes system (allowed automatic downloading of BG meters directly into a secure website, annotation of BG readings, and insulin dose and carbohydrate intake entry) in conjunction with monthly “telematic” visits</td>
<td>Control group 31.5 ± 9.0; Intervention group 32.3 ± 10.1</td>
<td>N=154, 47.4% M; Intervention group 42.4% M</td>
<td>Significant improvement in HbA1c, increased knowledge about their diabetes, and increased adherence to DSM tasks in all subjects; decreased time attending visits and less time required from diabetes team in intervention group</td>
<td>“Telematic” visits not defined; may not address issues specific to emerging adults</td>
</tr>
<tr>
<td>Powell et al.</td>
<td></td>
<td>Virtual clinic designed for insulin pump users that offered access to health information, communication with health care providers via email and “ask the expert” sessions, and interaction with peers</td>
<td>NR (22–70)</td>
<td>N=17, %M NR</td>
<td>Users found participation in the virtual clinic reassuring; peer interaction piece seen as the most valuable component</td>
<td>No videoconferencing component; unclear if there was an electronic logbook; may not address issues specific to emerging adults—average duration of diabetes was 24 years</td>
</tr>
<tr>
<td>Ayatollahi et</td>
<td></td>
<td>Telemedicine system with both patient and provider platforms designed for use in developing countries where there is limited access to diabetes providers. <strong>Patient platform:</strong> logbook, data management capabilities, educational reading materials with embedded animations, and ways to contact the endocrinologist and the web administrator; <strong>Provider platform:</strong> list of patients who had updated their records or messaged the endocrinologist; patient diabetes and demographic/medical data, data analysis capabilities, prescribing and medical advice</td>
<td>NR</td>
<td>Phase 1: N=30 (7 children/patients, 23 parents). Phase 2: 15 endocrinologists %M NR in either group</td>
<td>System development No videoconferencing component; limited data entry based on the needs of the patient population being studied; presented to parents of pediatric patients with T1D and emerging adults with T1D but the two groups’ results were not separated; may not address issues specific to emerging adults</td>
<td></td>
</tr>
<tr>
<td>et al.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
their insulin pumps, blood glucose meters, and continuous glucose
monitors immediately prior to their visit so the data could be reviewed
by the diabetes provider. The intervention managed to engage emerging
adults with T1D in their care for the 1 year of study. There was a significant
increase in attendance at visits in the intervention group (p<0.0001) both
compared to the control group and to themselves in the year before they
participated in the study. This result was clinically meaningful as well: 74% of
individuals in the intervention group attended four visits during the year
of study, while no one in the control group attended four visits during the
same period of time. Furthermore, those in the intervention group reported
greater satisfaction with the care they received.\(^1,2,3\)

Additionally, a mobile phone service that successfully reduced the
incidence of diabetic ketoacidosis in emerging adults with poorly controlled
T1D,\(^4\) and a review of apps that had the potential to support safe drinking
practices in this age group but were not used for that purpose,\(^5,6\) have been
described. No other literature discussing telemedicine services specifically
for emerging adults was found.

### Diabetes technology use—clinical outcomes

Users of diabetes technology (apps, etc.) have reported high levels of
satisfaction with such systems.\(^7,8\) Increased use of such technology is
strongly correlated with improved diabetes management, including improved
knowledge about diabetes and improved DSM behaviors such as blood
glucose monitoring and insulin administration.\(^9\) Information on any
observed improvements in glycemic control were not presented, but it
follows that glycemic control should improve based on the improvement
in DSM behaviors. However, technology is not being utilized on a regular
basis in the transition-aged patient population (13–25 years old),\(^10\) and
when used, the use of these services wanes over time.\(^11\) Additionally, high
attrition in telemedicine services for T1D (up to 37% in a group who
were 92% white) has been reported,\(^12,13\) though one program (CoYoT1)
was able to keep their study participants engaged with their diabetes
care team over the course of 1 year using videoconferencing services.\(^14,15\)
Any interactive technology aimed at enhancing diabetes care and
self-management needs to be developmentally appropriate to the
patient’s age, abilities, sensitivities, lifestyle, and cultural nuances in order
to have a chance to be successful.\(^16\)

### Summary

Emerging adults with T1D often find it challenging to manage their
diabetes well because of the many competing priorities they are juggling
during this time. Since they are already high users of the internet and
mobile internet, telemedicine may help them keep them engaged with
their diabetes providers during this highly transitional period. There are
very few multi-component telemedicine services available for individuals
with T1D, and none of them provide a comprehensive technology-based
system. An electronic logbook, education services, a messaging service
with providers (text/e-mail/etc.), videoconferencing for follow-up visits, and
social networking with peers have all been included in these systems, and
each of these components was found to be beneficial. However, no one
system that has been described in the literature contained all components.

Additionally, while these multi-component T1D telemedicine systems often
included emerging adults in the group under study, the average age of the
study subjects was usually above the age range of emerging adulthood. The
one study that focused on creating a service for emerging adults (CoYoT1)
did not include any variations for cultural diversity or for differing needs
throughout emerging adulthood. This suggests that specific developmental
needs of emerging adults are not being addressed by these telemedicine
systems, nor are issues faced by diverse populations. More research
needs to be done to address which telemedicine services, if any, would be
beneficial for this especially vulnerable population.

### References

12. Mayr S. Use tests, apps, and Skype to keep young people with diabetes engaged with services, says guidance. AMI. 2016;37:2139A.